Lipoprotein(a) as a therapeutic target in cardiovascular disease

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 7, 2014, Pages 747-757

  Koschinsky, Marlys ^a   Boffa, Michael ^a  

^a UNIVERSITY OF WINDSOR   (Canada)

Author keywords

Atherosclerosis; Cardiovascular disease; Lipoprotein(a); Therapeutics

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DNA VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; NEUTRALIZING ANTIBODY; NICOTINIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; POLYCLONAL ANTIBODY; PROTEIN KINASE B; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT;

ANGIOGENESIS; AORTA STENOSIS; APOPTOSIS; ATHEROSCLEROSIS; BLOOD CHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DNA IMMUNIZATION; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MENDELIAN RANDOMIZATION ANALYSIS; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PLASMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN(A);

EID: 84902484753     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.920326     Document Type: Review

References (87)

1. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of CVD: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012;60(8):716-21
2. Boffa MB, Koschinsky ML. Update on lipoprotein(a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep 2013;15(10):360-6
3. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330(6144):132-7
4. Gabel BR, Koschinsky ML. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry 1995;34(48):15777-84
5. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003;14(4):361-6
6. Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)- lipoprotein concentrations in plasma. J Clin Invest 1987;80(2):458-65
7. van der Hoek YY, Wittekoek ME, et al. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet 1993;2(4):361-6
8. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993;2(7):933-40
9. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004;37(5):333-43
10. Koschinsky ML, Marcovina SM. Lipoprotein(a). In: Ballantyne CM, editor. Clinical lipidology: a companion to braunwalds heart disease. Saunders Elsevier, Philadelphia; 2009. p. 130-43
11. Jacobson TA. Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc 2013;88(11):1294-311
12. Trégouët DA, Keonig IR, Erdmann J, et al. Genome-wide haplotype association study identifies the SLC22A3- LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009;41(3):283-5
13. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301(22):2331-9
14. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361(26):2518-28
15. Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein (a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010;55(19):2160-7
16. Hopewell JC, Seedorf U, Farrall M, et al. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med 2013;In press
17. IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet 2011;7(9):e1002260
18. Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol 2013;33(12):2902-8
19. ODonoghue M, Morrow DA, Tsimikas S, et al. Lipoprotein (a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol 2014;63(6):520-7
20. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274(22):1771-4
21. Marburger C, Hambrecht R, Niebauer J, et al. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am J Cardiol 1994;73(11):742-6
22. Berg K, Dahlén G, Christophersen B, et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997;52(5):254-61
23. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial. Circulation 2014;129(6):635-42
24. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368(6):503-12
25. Kamstrup PR, Tybjrg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014;63(5):470-7
26. Guerra R, Yu Z, Marcovina S, et al. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation 2005;111(12):1471-9
27. Erbel R, Lehmann N, Churzidse S, et al. Gender-specific association of coronary artery calcium and lipoprotein parameters: the Heinz Nixdorf Recall Study. Atherosclerosis 2013;229(2):531-40
28. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994;93(6):2758-63
29. Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol 1999;10(2):133-41
30. White AL, Guerra B, Lanford RE. Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. J Biol Chem 1997;272(2):5048-55
31. Becker L, Cook PM, Koschinsky ML. Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation. Biochemistry 2004;43(31):9978-88
32. Cain WJ, Millar JS, Himebauch AS, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res 2005;46(12):2681-91
33. Kostner KM, Maurer G, Huber K, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996;16(8):905-11
34. Hoover-Plow J, Huang M. Lipoprotein (a) metabolism: potential sites for therapeutic targets. Metabolism 2013;62(4):479-91
35. Rader DJ, Mann WA, Cain W, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp (a) in humans. J Clin Invest 1995;95(3):1403-8
36. Kraft HG, Lingenhel A, Raal FJ, et al. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20(2):522-8
37. Yang XP, Amar MJ, Vaisman B, et al. Scavenger receptor-BI is a receptor for lipoprotein(a). J Lipid Res 2013;54(9):2450-7
38. Grainger DJ, Kemp PR, Liu AC. Activation of transforming growth factorbeta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370(6489):460-2
39. Qin SY, Liu J, Jiang HX, et al. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies. Atherosclerosis 2013;227(2):360-6
40. Kamstrup PR, Tybjrg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol 2012;32(7):1732-41
41. Spence JD, Koschinsky M. Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both? Arterioscler Thromb Vasc Biol 2012;32(7):1550-1
42. Cho T, Jung Y, Koschinsky ML. Apolipoprotein(a), through its strong lysine-binding site in KIV(10), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/ MYPT1-dependent pathway. J Biol Chem 2008;283(45):30503-12
43. Cho T, Romagnuolo R, Scipione C, et al. Apolipoprotein(a) stimulates nuclear translocation of b-catenin: a novel pathogenic mechanism for lipoprotein(a). Mol Biol Cell 2013;24(3):210-21
44. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353(1):46-57
45. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008;49(10):2230-9
46. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med 2011;5(5):673-94
47. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 2010;12(5):467-82
48. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363(25):2406-15
49. Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res 2012;53(12):2515-24
50. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59(25):2344-53
51. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on lowdensity lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012;60(19):1888-98
52. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367(20):1891-900
53. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterollowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126(20):2408-17
54. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308(23):2497-506
55. Desai NR, Kohli P, Giugliano RP, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein (a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 2013;128(9):962-9
56. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356(2):148-56
57. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381(9860):40-6
58. Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008;5(8):497-505
59. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statintreated dyslipidemia. N Engl J Med 2010;362(10):906-16
60. Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010;5(12):e14328
61. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75(5):898-915
62. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 2008;52(2):124-31
63. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255-67
64. Albers JJ, Slee A, OBrien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/ High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013;62(17):1575-9
65. Besseling J, Hovingh GK, Stroes ES. Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises. Neth J Med 2013;71(3):118-22
66. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9719):998-1006
67. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebocontrolled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126(19):2283-92
68. McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012;7(11):e49006
69. Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013;62(23):2178-84
70. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statinintolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012;33(9):1142-9
71. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31(23):2844-53
72. Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 2011;57(15):1611-21
73. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010;208(2):317-21
74. Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6(3):229-39
75. Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)- hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013;128(24):2567-76
76. Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013;14(1):93-9
77. Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest 2011;121(9):3724-34
78. Chennamsetty I, Claudel T, Kostner KM, et al. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol 2012;32(5):1220-7
79. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia. Atherosclerosis 1982;44(1):61-71
80. Dobs AS, Prasad M, Goldberg A, et al. Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing longterm treatment with lipid-lowering drugs. Cardiovasc Drugs Ther 1995;9(5):677-84
81. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002;48(9):1454-9
82. Kyutoku M, Nakagami H, Koriyama H, et al. Inhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a). Sci Rep 2013;3:1600
83. Edelstein C, Pfaffinger D, Hinman J, et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential proinflammatory properties to human apolipoprotein(a). J Biol Chem 2003;278(52):52841-7
84. Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010;56(12):946-55
85. van Dijk RA, Kolodgie F, Ravandi A, et al. Differential expression of oxidationspecific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012;53(12):2773-90
86. Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res 2013;54(10):2815-30
87. Brown WV, Ballantyne CM, Jones PH, Marcovina S. Management of Lp(a). J Clin Lipidol 2010;4(4):240-7